230 related articles for article (PubMed ID: 26943589)
21. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
Zhong Q; Peng HL; Zhao X; Zhang L; Hwang WT
Clin Cancer Res; 2015 Jan; 21(1):211-20. PubMed ID: 25348513
[TBL] [Abstract][Full Text] [Related]
22. Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis.
Sabatier R; Lavit E; Moretta J; Lambaudie E; Noguchi T; Eisinger F; Cherau E; Provansal M; Livon D; Rabayrol L; Popovici C; Charaffe-Jauffret E; Sobol H; Viens P
Fam Cancer; 2016 Oct; 15(4):497-506. PubMed ID: 26833043
[TBL] [Abstract][Full Text] [Related]
23. Novel BRCA1/2 mutations in Serbian breast and breast-ovarian cancer patients with hereditary predisposition.
Dobricić J; Branković-Magić M; Filipović S; Radulović S
Cancer Genet Cytogenet; 2010 Oct; 202(1):27-32. PubMed ID: 20804917
[TBL] [Abstract][Full Text] [Related]
24. Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics.
Moreno L; Linossi C; Esteban I; Gadea N; Carrasco E; Bonache S; Gutiérrez-Enríquez S; Cruz C; Díez O; Balmaña J
Clin Transl Oncol; 2016 Oct; 18(10):981-7. PubMed ID: 26742938
[TBL] [Abstract][Full Text] [Related]
25. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
[TBL] [Abstract][Full Text] [Related]
26. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
[TBL] [Abstract][Full Text] [Related]
27. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
Kauff ND; Mitra N; Robson ME; Hurley KE; Chuai S; Goldfrank D; Wadsworth E; Lee J; Cigler T; Borgen PI; Norton L; Barakat RR; Offit K
J Natl Cancer Inst; 2005 Sep; 97(18):1382-4. PubMed ID: 16174860
[TBL] [Abstract][Full Text] [Related]
28. Decision-making on preimplantation genetic diagnosis and prenatal diagnosis: a challenge for couples with hereditary breast and ovarian cancer.
Derks-Smeets IA; Gietel-Habets JJ; Tibben A; Tjan-Heijnen VC; Meijer-Hoogeveen M; Geraedts JP; van Golde R; Gomez-Garcia E; van den Bogaart E; van Hooijdonk M; de Die-Smulders CE; van Osch LA
Hum Reprod; 2014 May; 29(5):1103-12. PubMed ID: 24603131
[TBL] [Abstract][Full Text] [Related]
29. Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes.
Cochran RL; Cidado J; Kim M; Zabransky DJ; Croessmann S; Chu D; Wong HY; Beaver JA; Cravero K; Erlanger B; Parsons H; Heaphy CM; Meeker AK; Lauring J; Park BH
Oncotarget; 2015 Sep; 6(28):25240-51. PubMed ID: 26246475
[TBL] [Abstract][Full Text] [Related]
30. Hereditary cancer syndromes.
Fostira F; Thodi G; Konstantopoulou I; Sandaltzopoulos R; Yannoukakos D
J BUON; 2007 Sep; 12 Suppl 1():S13-22. PubMed ID: 17935271
[TBL] [Abstract][Full Text] [Related]
31. Genetic alterations in hereditary breast cancer.
Cipollini G; Tommasi S; Paradiso A; Aretini P; Bonatti F; Brunetti I; Bruno M; Lombardi G; Schittulli F; Sensi E; Tancredi M; Bevilacqua G; Caligo MA
Ann Oncol; 2004; 15 Suppl 1():I7-I13. PubMed ID: 15280181
[TBL] [Abstract][Full Text] [Related]
32. Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers.
Lee YJ; Lee SW; Kim KR; Jung KH; Lee JW; Kim YM
J Gynecol Oncol; 2017 Jan; 28(1):e3. PubMed ID: 27670257
[TBL] [Abstract][Full Text] [Related]
33. Italian family with two independent mutations: 3358T/A in BRCA1 and 8756delA in BRCA2 genes.
Cortesi L; Turchetti D; Bertoni C; Zanocco-Marani T; Vinceti M; Silvestri C; Federico M; Silingardi V; Ferrari S
Eur J Hum Genet; 2003 Mar; 11(3):210-4. PubMed ID: 12673274
[TBL] [Abstract][Full Text] [Related]
34. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
35. Hereditary breast and ovarian cancer susceptibility genes (review).
Kobayashi H; Ohno S; Sasaki Y; Matsuura M
Oncol Rep; 2013 Sep; 30(3):1019-29. PubMed ID: 23779253
[TBL] [Abstract][Full Text] [Related]
36. Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests.
Pujol P; Lyonnet DS; Frebourg T; Blin J; Picot MC; Lasset C; Dugast C; Berthet P; de Paillerets BB; Sobol H; Grandjouan S; Soubrier F; Buecher B; Guimbaud R; Lidereau R; Jonveaux P; Houdayer C; Giraud S; Olschwang S; Nogue E; Galibert V; Bara C; Nowak F; Khayat D; Nogues C
Breast Cancer Res Treat; 2013 Aug; 141(1):135-44. PubMed ID: 23974829
[TBL] [Abstract][Full Text] [Related]
37. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
[TBL] [Abstract][Full Text] [Related]
38. BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling.
Nicoletto MO; Donach M; De Nicolo A; Artioli G; Banna G; Monfardini S
Cancer Treat Rev; 2001 Oct; 27(5):295-304. PubMed ID: 11871866
[TBL] [Abstract][Full Text] [Related]
39. Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel.
Moran O; Nikitina D; Royer R; Poll A; Metcalfe K; Narod SA; Akbari MR; Kotsopoulos J
Breast Cancer Res Treat; 2017 Jan; 161(1):135-142. PubMed ID: 27798748
[TBL] [Abstract][Full Text] [Related]
40. RAD51C mutation screening in high-risk patients from Serbian hereditary breast/ovarian cancer families.
Krivokuca A; Yanowski K; Rakobradovic J; Benitez J; Brankovic-Magic M
Cancer Biomark; 2015; 15(6):775-81. PubMed ID: 26406419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
